Mezlocillin is subject to dose-dependent pharmacokinetics. Previous studies have examined the pharmacokinetic but not the pharmacodynamic aspects of this effect. The pharmacokinetic disposition of meziocillin was determined in eight healthy volunteers in a randomized, crossover fashion after single infusions of 50 and 80 mg of mezlocillin per kg of body weight. Plasma and urine were assayed with a specific high-pressure liquid chromatography assay and analyzed by noncompartmental methods. Pharmacodynamic (bactericidal) effects were evaluated from serial serum bactericidal titers obtained after each dose by using the area under the bactericidal activity curve method. The mean mezlocillin total body clearance decreased from 203.6 ± 36.2 ml/min after the 50-mg/kg dose to 171.7 + 42.1 ml/min after the 80-mg/kg dose (P, 0.01). The decreased clearance was reflected by a decrease in nonrenal clearance only (108.9 ± 20.0 to 77.9 ± 23.5 ml/min, respectively; P, 0.001). Mean areas under the curve for concentration in plasma versus time normalized to the 50-mg/kg dose were 314 ± 73 and 375 -+-64 ,ug. h/ml for the low and high doses, respectively (P, 0.01). No significant changes were observed in the steady-state volume of distribution or elimination half-life. Mean areas under the bactericidal activity curve were 100 ± 77 and 244 ± 143 for the 50-and 80-mg/kg doses, respectively. The decrease in mezlocillin clearance and the disproportionate increase in the area under the curve for concentration in plasma versus time, coupled with the observed prolonged bactericidal effects of the 80-mg/kg dose, lend support for administration of mezlocillin at a higher dose less frequently (e.g., 5 g every 8 h). Clinical trials with the higher-dose regimen are warranted to validate these observations.
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Mezlocillin is an acylureidopenicillin with a broad antimicrobial spectrum and proven clinical efficacy in serious infections (11, 13) . Mezlocillin, like other acylureidopenicillins, is subject to dose-dependent pharmacokinetics. As the dose is increased, disproportionate increases in concentrations in plasma and areas under the curve (AUC) for concentration in plasma versus time result (3, 8) . Previous studies have evaluated the dose dependency of mezlocillin pharmacokinetics after single 1-, 2-, and 5-g doses (3, 8) and in multiple doses of 4 g every 6 h versus 5 g every 8 h (4). To date, no attempt has been made to directly correlate the saturable elimination properties of mezlocillin with the pharmacodynamic (bactericidal) activity of this agent to assess the feasibility of administering larger doses with longer dosing intervals. Such an approach to dosing mezlocillin would be more convenient to administer and less costly. The purpose of this investigation was to determine the extent of concentration-dependent pharmacokinetics of mezlocillin at clinically used doses and to evaluate the impact of the pharmacokinetics on the serum bactericidal activity of mezlocillin over time. Lambda Max variable-wavelength detector (Waters), and a C18 5-,um (4.6 mm by 25 cm) column (Alltech Associates, Inc.). The mobile phase consisted of 35% acetonitrile and 0.2% H3PO4 adjusted to a pH of 3.0. The flow rate was 1 ml/min, with a sensitivity of 0.05 absorbance units (full scale) x 5 mV, with a chart speed of 0.25 cm/min, and a detector setting of 220 nm. Concentrations of 0.5 jg/ml were detectable in plasma without extraction. The detection limit for urine is 1.0 jig/ml. The interday variability of mezlocillin concentrations in plasma was 8.5% at 45 jig/ml and 9.5% at 4.5 jig/ml, while the intraday variability was less than 6%.
MATERIALS AND METHODS

Subjects
Bactericidal analysis. The bactericidal activity of mezlocillin was determined in serum against Staphylococcus aureus ATCC 29213, which required an MBC of 2 jig of mezlocillin per ml by standard broth macrodilution methods (9) .
Serum bactericidal titers were determined by the method of Reller and Stratton (12) . Serum bactericidal titers were determined in triplicate with microtiter trays by the following procedure. Cation-supplemented Mueller-Hinton broth (50 jil) was added to all tray wells except for those in column 1. A 50-jil serum sample was then added to columns 1 Pharmacodynamic analysis. Pharmacodynamic analysis was accomplished by using the area under the curve for bactericidal activity (AUBC) (2) . The AUBC, a dimensionless value, was determined by plotting the reciprocal of serum bactericidal titers versus time and applying the trapezoidal rule.
Statistical analysis. Statistical significance was determined by using the paired t test on mean data. A P value of 0.05 or less was considered significant. RESULTS Pharmacokinetic analysis. Curves for the mean concentration in plasma versus time for the low-dose regimen and for the high-dose regimen normalized to 50 mg/kg were plotted (Fig. 1) . For both doses, mezlocillin concentrations were below the detectable limit (0.5 ,ug/ml) in plasma at 12 and 24 h after the dose. The mean pharmacokinetic parameters (+ standard deviation) for both doses were calculated ( Table 1) . The mean total body clearance of mezlocillin was 203.6 + 36.2 ml/min with the 50-mg/kg dose and decreased significantly to 171.7 + 42.1 ml/min with the 80 mg/kg dose (P, 0.01). The decrease in total body clearance was reflected entirely by a decrease in nonrenal clearance from a mean of 108.9 ± 20.0 to 77.9 + 23.5 ml/min with the low and high doses, respectively (Table 1 ; P, 0.001). Mean renal clearance was essentially unchanged ( Table 1) .
The AUC for concentration in plasma versus time also increased disproportionately as a consequence of decreased total body clearance (Table 1) . Mean AUC for the 50-mg/kg dose was 314 + 73 ,ug. h/ml compared with a mean of 600 + 102 ,ug h/ml with the 80-mg/kg dose. If the kinetics of mezlocillin were linear, the AUC with the higher dose would be expected to increase to roughly 1.6 times that of the low dose. Our results reveal a twofold increase in AUC with the high dose. The AUC with the high dose normalized to 50 mg/kg was 375 + 64 ig h/ml and was significantly different from the AUC with the low dose ( For 80-mg/kg dose normalized to 50 mg/kg. (Fig. 2) . Mean reciprocal serum bactericidal titers (± standard deviation) were 53 ± 36 and 128 ± 59 at 25 min, 3.25 ± 1 and 5.0 ± 2 at 4 h, and 1.5 ± 0.5 and 2.25 ± 0.7 at 6 h for the low and high doses, respectively (Fig. 2) . A mean reciprocal serum bactericidal titer of 1.4 ± 0.5 was observed at 8 h with the 80-mg/kg dose (Fig. 2) , but only one subject had a measurable titer (1:2) at 8 h after the 50-mg/kg dose. There was no detectable serum bactericidal activity at 12 and 24 h with either dose. The mean AUBC (± standard deviation) for the low-dose regimen was 100 ± 77 compared with a mean AUBC of 244 ± 143 with the high dose. This difference represents a 2.4-fold increase in bactericidal activity with the high dose (P, 0.03), yet the dose was increased only by a factor of 1.6. DISCUSSION Previous investigators have shown that mezlocillin possesses dose-dependent pharmacokinetics (3, 8) . The majority of these studies have been carried out by comparing a very low dose (usually 1 or 2 g) with a much higher dose (usually 5 g). Bergan (3) noted a 20% decrease in mezlocillin total body clearance with a 2.5-fold increase in dose. (4) made no attempt to directly determine the pharmacodynamic differences between these two regimens. They did suggest, however, that achievable levels in serum and pub- (2) . Measurement of pharmacodynamic activity by methods similar to the AUBC method has been used to assess the immunosuppressive activity of corticosteroids in human plasma (5) and the pharmacodynamic effects of warfarin by measuring AUC for prothrombin activity (10) . Using the AUBC approach, we found an enhancement of bactericidal effect beyond what might be predicted if mezlocillin kinetics were linear in nature (Fig. 2) . In fact, if the sum of the total daily AUBC for a 50-mg/kg dose given every 4 h is compared with the total daily AUBC for an 80-mg/kg dose given every 8 h, similar total daily AUBCs can be calculated (597 ± 465 versus 732 ± 430, respectively; P, 0.538). Results from this analysis provide support for the regimen 'of a higher dose less frequently administered.
In summary, the results of this investigation confirm that mezlocillin kinetics are significantly dose dependent with doses that are likely to be 'Used clinically and that this effect correlates directly with a prolongation of bactericidal activity with the higher dose. These results taken together lend support for the administration of mezlocillin in doses that are higher than currently recommended but administered less frequently (e.g., 5 g every 8 h). Such a regimen would allow improved convenience with less cost. Clinical trials validating this dosing scheme, compared with standard dosing regimens, are warranted.
